To treat diffuse substantial B-cell lymphoma, not normally specified, or massive B-mobile lymphoma arising from follicular lymphoma soon after two or maybe more traces of systemic therapy The FDA publishes a observe from the petitions under FDA review in the public Federal Sign up. The FDA evaluates the petition, https://peterd394ctl1.wikiusnews.com/user